ArticleFrontiers in endocrinology2026
Sulodexide for limb salvage in refractory diabetic foot ulcer with arteriosclerosis obliterans: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endovascular Intervention and the Vascular Glycocalyx in Patients with Chronic Limb-Threatening Ischaemia: A Prospective Observational Study.International journal of molecular sciences · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with diabetic foot ulcers (DFU) remain at substantial risk for impaired wound healing, even following successful revascularization. This clinical challenge is often associated with underlying microcirculatory dysfunction, highlighting a critical unmet need for effective intervention strategies. Case description: A 77-year-old female patient was suffering from severe DFU on her right foot, with infected wound, complicated by arteriosclerosis obliterans of the lower limbs. She underwent surgical debridement and angiographically and hemodynamically successful endovascular angioplasty. Despite these interventions and restored macrovascular perfusion, the wound exhibited continuously deterioration, and the patient was at imminent risk of minor amputation. Therefore, persistent microcirculatory dysfunction was considered a major contributing factor to the poor healing response, prompting the initiation of a salvage regimen with intravenous Sulodexide (600 LSU/day). Following a 51-day Sulodexide treatment, complete wound healing was achieved and the patient was discharged. Conclusion: This case report suggests that highly selected DFU patients unresponsive to standard therapies including successful revascularization, Sulodexide may be a plausible salvage or adjunctive therapeutic option. This observation is strictly hypothesis-generating and its potential role warrants investigation in future prospective clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.